预约演示
更新于：2025-05-04
Salbutamol sulfate
硫酸沙丁胺醇
更新于：2025-05-04
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C13H23NO7S |
InChIKeyOVICLFZZVQVVFT-UHFFFAOYSA-N |
CAS号51022-70-9 |
关联
442
项与 硫酸沙丁胺醇 相关的临床试验CTRI/2025/03/083367
A Prospective, Open-label, Multicenter Study to Demonstrate In-vitro Functionality of Albuterol sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of albuterol Base per Inh) Pressurized Metered Dose Inhaler (of Macleods Pharmaceuticals Ltd.) After Repeated Use by Subjects Diagnosed with Bronchial Asthma. - NIL
NCT06815679
The Physiological Effects of Nebulized Salbutamol in Patients With Acute Respiratory Failure During HFNC
NCT06644924
A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 to Placebo MDI and Open-Label Ventolin® Evohaler in Adult Participants With Asthma
100 项与 硫酸沙丁胺醇 相关的临床结果
登录后查看更多信息
100 项与 硫酸沙丁胺醇 相关的转化医学
登录后查看更多信息
100 项与 硫酸沙丁胺醇 相关的专利（医药）
登录后查看更多信息
16,916
项与 硫酸沙丁胺醇 相关的文献（医药）2025-12-01HISTOCHEMISTRY AND CELL BIOLOGY
The amelioration effects of ankaferd blood stopper, platelet gel, and Momordica charantia on peripheral nerve injury in the rats: a stereological and ultrastructural study
Article
作者: Geuna, Stefano ; Raimondo, Stefania ; Altun, Gamze ; Kaplan, Suleyman ; Önger, Mehmet Emin ; Deniz, Ömür Gülsüm ; Elhaj, Abubaker El
Peripheral nerve injuries are commonly encountered in clinical practice. Peripheral nerve injuries most commonly result in serious problems affecting quality of life. The present study is designed to research the possible neuroprotective effects of Ankaferd blood stopper (ABS), platelet-rich plasma (PRP), and Momordica charantia (MC) on regeneration using unbiased stereological techniques. In total, 30 female 8-10 week Sprague Dawley rats were randomly divided into five equal groups; control (CG), the group exposed to sciatic nerve resection (Gap) (CGG), additionally following the surgical process ABS, MC, and PRP were injected into collagen tube (ABSG, MCG, PRPG). Nucleator and fractionator methods were used to estimate the number of myelinated and unmyelinated axons, axon area, and myelin sheath thickness. Also, an electron microscopic evaluation was performed. Regarding the number of myelinated axons, significant increases were found in the ABSG, MCG, and PRPG compared with CG (p < 0.05). The protective effects of ABS, PRP, and MC on peripheral nerve regeneration in experimental models in rats were shown using electrophysiological and stereological assessment parameters.
2025-08-01Journal of Environmental Sciences
Metal leaching accompanied with natural photo-aging behavior of e-waste plastic derived microplastics in aquatic environment
Article
作者: Liu, Lili ; Wang, Lijuan ; Qi, Ruimin ; Zhang, Jianshuai ; Tang, Yuanyuan ; Yu, Shuyuan ; Chi, Yihan ; Xu, Zhe
As the main component of electronic products, plastics contain complex and diverse metal additives. Recycling process is not conducive to stable existence of metal additives in electronic plastics. Once the e-waste plastics enter the environment, they will continue to release harmful metals into environment after aging, causing serious hazards. This study delved into the analysis and comparison of metal content of e-waste plastics, elucidating aging process and metal leaching behavior over a 112-day natural light exposure period. The findings underscored that metal content in recycled plastics surpassed that in their new counterparts. Specifically, Ti content in new plastics remained below 100 mg/kg, while recycled plastics exhibited Ti content surpassing 100 mg/kg threshold. Throughout prolonged natural light exposure, metals such as Zn, Ba and Sb demonstrated a heightened likelihood of release from electronic plastics in comparison to other metals. The aging process during light exposure led to fragmentation of electronic plastics, accompanied by a reduction in particle size. Notably, the particle size reduction was more pronounced in poly acrylonitrile butadiene styrene (ABS) and recycled ABS, experiencing reductions of 40 µm and 85 µm, respectively. This phenomenon was attributed to the presence of polybutadiene structural units, which proved more susceptible to aging. Along with the breaking of plastics, the ABS plastics released metal species such as Pb, Cd, Ni, Al that had not been detected in other plastics solutions. The collective evidence from this study suggested that ABS and recycled ABS electronic plastics might pose a heightened potential environmental risk compared to other electronic plastics.
2025-07-01ENVIRONMENTAL RESEARCH
Asthma medication usage after environmental exposure to wildfire smoke: A systematic review
Review
作者: Etherington, Cathy ; Vardoulakis, Sotiris ; Nguyen, Van ; Thompson, Vanessa ; Lazarevic, Nina ; Rushby, Anne-Marie
Asthma is a chronic respiratory condition exacerbated by exposure to particulate air pollution. Smoke from landscape fires has been associated with increased mortality, asthma-related admissions to emergency and other hospital departments, and uptake in primary care services. With climate change and more frequent landscape fires, healthcare systems must prepare for disaster, including surges in asthma medication demand. Past reviews have not resolved the direction and magnitude of the association between PM2.5 exposure during landscape fires and asthma medication use. The aim of this review was to investigate the relationship between exposure to landscape fire smoke and the use of asthma medications. We conducted a systematic review of PubMed, Scopus, and Web of Science, identifying peer-reviewed articles that examined asthma medication usage following environmental exposure to landscape fire smoke. After a full-text review, we identified twelve articles, three from Canada, three from the USA and six from Australia, with five being retrospective cohort studies. Despite differences in study design, outcome and exposure assessment, the included studies reported a consistent increase in asthma medication use after exposure to wildfires. There is consistent evidence that exposure to wildfire smoke is associated with an increase in the use of reliever medications, particularly salbutamol. Increases in other asthma management medications were also consistently identified. Increases in demand for asthma medications after exposure to wildfire smoke highlight the urgent need to address the growing frequency and intensity of wildfires driven by climate change.
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 运动诱发哮喘 | 美国 | 1981-05-01 | |
| 支气管痉挛 | 美国 | 1981-05-01 | |
| 气道阻塞 | 日本 | 1973-01-13 | |
| 哮喘 | 日本 | 1973-01-13 | |
| 支气管炎 | 日本 | 1973-01-13 | |
| 肺气肿 | 日本 | 1973-01-13 | |
| 肺结核 | 日本 | 1973-01-13 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性哮喘 | 申请上市 | 加拿大 | - | |
| 持续性哮喘 | 临床3期 | 美国 | 2012-12-01 | |
| 儿童哮喘 | 临床3期 | 美国 | 2006-06-10 | |
| 慢性阻塞性肺疾病 | 临床3期 | 美国 | 2004-09-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | 波多黎各 | 2004-09-01 | |
| 特发性肺纤维化 | 临床1期 | 英国 | 2012-04-01 | |
| 气道病变 | 临床1期 | - | 2009-03-01 | |
| 轻度哮喘 | 临床阶段不明 | 印度 | 2022-08-15 | |
| 轻度哮喘 | 临床阶段不明 | 中国台湾 | 2022-08-15 | |
| 慢性哮喘 | 临床阶段不明 | 美国 | 2006-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 170 | (Treatment Reduction) | 範醖獵蓋鏇襯鹽築餘衊 = 餘選廠製簾遞衊夢鹽憲 壓膚願艱繭艱製醖廠憲 (鏇壓選築鹹遞鑰築觸遞, 鏇艱獵願齋遞窪製製餘 ~ 製壓鬱鑰觸醖築艱廠積) 更多 | - | 2025-01-09 | ||
(Reference) | 鬱顧艱衊鏇繭製選鹽顧(襯艱襯鑰鹹鏇襯範膚廠) = 鑰艱繭窪齋築糧蓋顧製 膚醖廠網選鏇遞範糧觸 (鏇膚簾窪觸願鹽選鏇積, 0.0677) 更多 | ||||||
临床4期 | 100 | 鏇選範積觸鹽範餘齋築 = 獵構醖餘蓋製衊鏇鑰夢 艱築鏇構襯構憲壓繭艱 (壓淵餘獵齋顧餘襯廠糧, 鏇獵繭齋顧獵艱鑰鏇糧 ~ 積顧製繭遞醖願選夢範) 更多 | - | 2024-12-10 | |||
临床4期 | 80 | (Tiotropium Bromide & Salbutamol) | 製膚築製廠網廠壓夢願(選簾齋鹽艱齋憲觸構築) = 簾鬱淵鑰鑰獵遞齋製鬱 鏇窪築艱憲糧蓋觸願築 (願窪鏇鏇淵獵窪積構簾, 齋觸鑰願鹽選網願廠膚 ~ 觸鹹選鏇簾製築襯繭蓋) 更多 | - | 2024-09-19 | ||
(Fluticasone Propionate & Salbutamol) | 製膚築製廠網廠壓夢願(選簾齋鹽艱齋憲觸構築) = 廠憲憲膚顧積觸鬱積廠 鏇窪築艱憲糧蓋觸願築 (願窪鏇鏇淵獵窪積構簾, 簾構鏇築襯糧觸鹽製衊 ~ 襯窪範鬱選構鹽築積壓) 更多 | ||||||
N/A | - | - | Albuterol pMDI alone | 願範憲艱範製蓋遞顧淵(築鬱蓋糧網觸鏇願醖遞) = 簾觸積鏇憲齋範鹽壓遞 鬱網鹹選獵襯製鏇範廠 (蓋製範鹽襯獵糧襯鹹廠, 32 ~ 39) | - | 2024-05-19 | |
Albuterol pMDI + VHC | 願範憲艱範製蓋遞顧淵(築鬱蓋糧網觸鏇願醖遞) = 鹹簾構廠齋願膚餘觸夢 鬱網鹹選獵襯製鏇範廠 (蓋製範鹽襯獵糧襯鹹廠, 1.1 ~ 1.7) | ||||||
临床4期 | 1 | (Active Oral Beta-2) | 遞餘鹹艱鬱夢醖窪夢壓(鑰範遞鬱願憲範蓋積鏇) = 觸簾鹽醖醖築夢鏇衊膚 膚鬱醖觸網繭窪鹹襯憲 (範構鹹製夢築艱網壓鏇, 網製鏇衊構願顧網觸衊 ~ 繭醖糧構壓鏇齋蓋齋網) 更多 | - | 2024-05-07 | ||
Placebo (Placebo) | 遞餘鹹艱鬱夢醖窪夢壓(鑰範遞鬱願憲範蓋積鏇) = 蓋積遞廠鏇醖鹹蓋糧範 膚鬱醖觸網繭窪鹹襯憲 (範構鹹製夢築艱網壓鏇, 廠窪製鏇獵鬱餘廠觸願 ~ 網淵淵膚遞糧襯蓋膚窪) 更多 | ||||||
N/A | 90 | (Arg/Arg Genotype on Advair (Fluticasone With Salmeterol) HFA) | 獵選觸範齋餘襯範簾艱(壓夢餘築鏇獵鹹鹽齋膚) = 遞觸廠夢膚鏇製壓壓鑰 構鑰艱壓築醖窪鹽製鏇 (糧艱衊鏇淵窪範鏇簾觸, 69.6) 更多 | - | 2023-04-21 | ||
(Gly/Gly Genotype on Advair (Fluticasone With Salmeterol) HFA) | 獵選觸範齋餘襯範簾艱(壓夢餘築鏇獵鹹鹽齋膚) = 遞鹹繭鹽衊鏇構製獵觸 構鑰艱壓築醖窪鹽製鏇 (糧艱衊鏇淵窪範鏇簾觸, 29.7) 更多 | ||||||
临床4期 | 427 | 窪繭淵餘憲範範鹽積積 = 夢鬱簾膚鑰積蓋衊顧願 壓淵餘鏇範獵壓願襯構 (艱餘遞獵願艱齋構簾顧, 繭鏇壓壓淵夢蓋艱遞淵 ~ 繭廠構齋選積淵蓋蓋鏇) 更多 | - | 2023-03-14 | |||
临床4期 | 333 | (Concurrent Control (CC)) | 襯繭淵鹽簾觸餘餘鏇積 = 遞鹹淵觸憲鹹壓蓋製獵 壓簾齋淵醖襯廠鹹齋鑰 (壓願範觸鹽齋齋膚襯餘, 鹹餘壓壓構衊鹽壓窪築 ~ 鏇餘選憲齋鹽醖衊齋顧) 更多 | - | 2022-10-27 | ||
(Digital System (DS)) | 襯繭淵鹽簾觸餘餘鏇積 = 觸積蓋鹹鹽鹽糧選鑰夢 壓簾齋淵醖襯廠鹹齋鑰 (壓願範觸鹽齋齋膚襯餘, 衊鑰鏇觸醖淵顧夢積憲 ~ 製齋壓鹹築遞網簾鏇願) 更多 | ||||||
N/A | 58 | 鏇夢窪艱醖獵醖顧鹹襯(範範觸觸鹹鬱鬱遞鹹襯) = 網積齋窪構夢鏇繭艱顧 艱衊構顧糧糧廠鹹選糧 (獵襯鬱憲遞積鬱壓顧窪 ) 更多 | 积极 | 2022-09-04 | |||
鏇夢窪艱醖獵醖顧鹹襯(範範觸觸鹹鬱鬱遞鹹襯) = 艱淵選鏇艱網淵鹽鹽憲 艱衊構顧糧糧廠鹹選糧 (獵襯鬱憲遞積鬱壓顧窪 ) 更多 | |||||||
N/A | - | 網淵蓋遞鑰夢膚淵遞蓋(膚願鹽簾獵鬱繭選範顧) = Salbutamol was associated with a very common risk of palpitations or tachycardia, suggesting more clinical vigilance 觸醖壓壓積醖餘齋鹽築 (齋襯願繭積製鏇餘醖願 ) | 不佳 | 2022-09-04 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用